{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:48:30Z","timestamp":1780058910984,"version":"3.54.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Drug-induced liver injury (DILI) is a prevalent and critical etiology of acute liver failure that often results in substantial health complications and mortality. Acipimox is a pharmacological agent used for lipid reduction, whereas telmisartan is prescribed for hypertension management. We report a case of severe DILI attributed to the concomitant use of acipimox and telmisartan, and we analyze the potential underlying mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 58-year-old female was admitted to our hospital with anorexia lasting &gt;6 months. The patient had a history of taking oral antihypertensive medication (telmisartan) and lipid-lowering medications (atorvastatin and acipimox), with suspected DILI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>The patient was diagnosed with DILI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>After discontinuation of the suspected hepatotoxic agents telmisartan and acipimox, the patient received anti-inflammatory therapy with glucocorticoids along with hepatoprotective treatment including glutathione, S-adenosylmethionine, and bicyclol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient\u2019s liver function has substantially normalized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This study is the first to highlight a significant case of severe liver injury resulting from concurrent administration of acipimox and telmisartan, which is potentially influenced by factors such as age, sex, drug interactions, and genetic polymorphisms. This study aimed to emphasize the significance of implementing precise and individualized treatment strategies for managing drug combinations for patients with multiple comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000044184","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T19:00:53Z","timestamp":1756494053000},"page":"e44184","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Severe drug-induced liver injury from acipimox and telmisartan co-administration: A case report and review of literature"],"prefix":"10.1097","volume":"104","author":[{"given":"Dan","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Geriatrics, The First Affiliated Hospital of China Medical University, Shenyang City, Liaoning Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, The First Affiliated Hospital of China Medical University, Shenyang City, Liaoning Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260406","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1053\/j.gastro.2019.02.002","article-title":"Incidence and etiology of drug-induced liver injury in Mainland China.","volume":"156","author":"Shen","year":"2019","journal-title":"Gastroenterology"},{"key":"R2-20260406","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/liv.15262","article-title":"Incidence and risk factors of drug-induced liver injury.","volume":"42","author":"Li","year":"2022","journal-title":"Liver Int"},{"key":"R3-20260406","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/14756366.2022.2037579","article-title":"Acipimox inhibits human carbonic anhydrases.","volume":"37","author":"Mori","year":"2022","journal-title":"J Enzyme Inhib Med Chem"},{"key":"R4-20260406","doi-asserted-by":"crossref","first-page":"116169","DOI":"10.1016\/j.biopha.2024.116169","article-title":"Effects of telmisartan on metabolic syndrome components: a comprehensive review.","volume":"171","author":"Imenshahidi","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"R5-20260406","doi-asserted-by":"crossref","first-page":"106786","DOI":"10.1016\/j.phrs.2023.106786","article-title":"Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).","volume":"192","author":"Qiu","year":"2023","journal-title":"Pharmacol Res"},{"key":"R6-20260406","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update.","volume":"17","author":"Danan","year":"2015","journal-title":"Int J Mol Sci"},{"key":"R7-20260406","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/apt.18116","article-title":"Characterisation of an outbreak of acute liver injury after ingestion of plant-based food supplement.","volume":"60","author":"Choi","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"R8-20260406","article-title":"Drug induced cholestatic liver diseases [published online ahead of print].","author":"Bjornsson","year":"2024","journal-title":"Hepatology"},{"key":"R9-20260406","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/toxsci\/kfae055","article-title":"Drug-induced impairment of mitochondrial fatty acid oxidation and steatosis: assessment of causal relationship with 45 pharmaceuticals.","volume":"200","author":"Buron","year":"2024","journal-title":"Toxicol Sci"},{"key":"R10-20260406","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jcph.23","article-title":"Drug-induced liver injury: the role of drug metabolism and transport.","volume":"53","author":"Corsini","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"R11-20260406","doi-asserted-by":"crossref","first-page":"118523","DOI":"10.1016\/j.jep.2024.118523","article-title":"HLA-B*35:01-mediated activation of emodin-specific T cells contributes to Polygonum multiflorum thunb.-induced liver injury in mice.","volume":"334","author":"Zeng","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"R12-20260406","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1248\/bpb.b24-00072","article-title":"Elucidating the mechanisms underlying interindividual differences in the onset of adverse drug reactions.","volume":"47","author":"Aoki","year":"2024","journal-title":"Biol Pharm Bull"},{"key":"R13-20260406","doi-asserted-by":"crossref","first-page":"124","DOI":"10.33160\/yam.2024.05.004","article-title":"Exploring acute liver damage: slimming health foods and CYP3A4 induction.","volume":"67","author":"Adachi","year":"2024","journal-title":"Yonago Acta Med"},{"key":"R14-20260406","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1751-2980.2009.00385.x","article-title":"Drug-induced liver disease: an 8-year study of patients from one gastroenterological department.","volume":"10","author":"Wang","year":"2009","journal-title":"J Dig Dis"},{"key":"R15-20260406","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4258\/hir.2023.29.3.246","article-title":"Development and verification of time-series deep learning for drug-induced liver injury detection in patients taking angiotensin II receptor blockers: a multicenter distributed research network approach.","volume":"29","author":"Heo","year":"2023","journal-title":"Healthc Inform Res"},{"key":"R16-20260406","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1055\/s-0034-1375959","article-title":"Drug-induced liver injury with autoimmune features.","volume":"34","author":"deLemos","year":"2014","journal-title":"Semin Liver Dis"},{"key":"R17-20260406","article-title":"Liver injury induced by acipimox in a patient with hyperlipidemia: a first case report.","author":"Qiu","year":"2020","journal-title":"Authorea"},{"key":"R18-20260406","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/cpt.1928","article-title":"UGT1A3 and sex are major determinants of telmisartan pharmacokinetics \u2013 a comprehensive pharmacogenomic study.","volume":"108","author":"Hirvensalo","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"R19-20260406","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(21)00113-3","article-title":"Treatment of type 2 diabetes: challenges, hopes, and anticipated successes.","volume":"9","author":"Nauck","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R20-20260406","doi-asserted-by":"crossref","first-page":"893","DOI":"10.5114\/aoms.2015.53311","article-title":"Telmisartan\/hydrochlorothiazide-induced hepatotoxicity.","volume":"11","author":"Lorena","year":"2015","journal-title":"Arch Med Sci"},{"key":"R21-20260406","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fphar.2014.00240","article-title":"Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury.","volume":"5","author":"Woodhead","year":"2014","journal-title":"Front Pharmacol"},{"key":"R22-20260406","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1463-1326.2011.01377.x","article-title":"Telmisartan, a dual ARB\/partial PPAR-\u03b3 agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes.","volume":"13","author":"Goyal","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"R23-20260406","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1161\/HYPERTENSIONAHA.109.143958","article-title":"Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways.","volume":"55","author":"He","year":"2010","journal-title":"Hypertension"},{"key":"R24-20260406","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/tox.22240","article-title":"Telmisartan ameliorates carbon tetrachloride-induced acute hepatotoxicity in rats.","volume":"32","author":"Atawia","year":"2017","journal-title":"Environ Toxicol"},{"key":"R25-20260406","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejphar.2012.07.049","article-title":"Therapeutic role of telmisartan against acetaminophen hepatotoxicity in mice.","volume":"693","author":"Fouad","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"R26-20260406","doi-asserted-by":"crossref","first-page":"107963","DOI":"10.1016\/j.intimp.2021.107963","article-title":"Telmisartan alleviates alcohol-induced liver injury by activation of PPAR-gamma\/Nrf-2 crosstalk in mice.","volume":"99","author":"Abdelhamid","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"R27-20260406","doi-asserted-by":"crossref","first-page":"174713","DOI":"10.1016\/j.ejphar.2021.174713","article-title":"Telmisartan relieves liver fibrosis and portal hypertension by improving vascular remodeling and sinusoidal dysfunction.","volume":"915","author":"Zheng","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"R28-20260406","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1124\/dmd.106.009761","article-title":"Genetic variants of human UGT1A3: functional characterization and frequency distribution in a Chinese Han population.","volume":"34","author":"Chen","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"R29-20260406","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/hep.20131","article-title":"Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4.","volume":"39","author":"Ehmer","year":"2004","journal-title":"Hepatology"},{"key":"R30-20260406","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/FPC.0b013e3283489ce2","article-title":"Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose.","volume":"21","author":"Ieiri","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"R31-20260406","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.29152","article-title":"Drug rechallenge following drug-induced liver injury.","volume":"66","author":"Hunt","year":"2017","journal-title":"Hepatology"},{"key":"R32-20260406","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jacl.2007.04.003","article-title":"The role of nicotinic acid metabolites in flushing and hepatotoxicity.","volume":"1","author":"Stern","year":"2007","journal-title":"J Clin Lipidol"},{"key":"R33-20260406","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.intimp.2015.05.045","article-title":"Nicotinic acid prevents experimental liver fibrosis by attenuating the prooxidant process.","volume":"28","author":"Arauz","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"R34-20260406","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-physiol-021119-034610","article-title":"Aging and lung disease.","volume":"82","author":"Cho","year":"2020","journal-title":"Annu Rev Physiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:01:29Z","timestamp":1775455289000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":34,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044184","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"2025-01-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}